公司,242,0.05583756345177665,n
年,81,0.01868943239501615,m
药品,63,0.014536225196123673,n
风险,52,0.011998154130133826,n
影响,47,0.010844485463774804,vn
产品,47,0.010844485463774804,n
万元,46,0.010613751730503,m
月,36,0.008306414397784956,m
经营,33,0.007614213197969543,vn
生产,33,0.007614213197969543,vn
企业,31,0.007152745731425935,n
通信,25,0.005768343331795108,j
项目,23,0.0053068758652515,n
价格,23,0.0053068758652515,n
政策,22,0.005076142131979695,n
主要,21,0.004845408398707891,b
核心,21,0.004845408398707891,n
市场,21,0.004845408398707891,n
可能,21,0.004845408398707891,v
投资,20,0.0046146746654360865,vn
资金,20,0.0046146746654360865,n
行业,19,0.004383940932164283,n
发展,19,0.004383940932164283,vn
不能,19,0.004383940932164283,v
一定,19,0.004383940932164283,d
管理,19,0.004383940932164283,vn
运营商,18,0.004153207198892478,n
控制,18,0.004153207198892478,v
占,17,0.003922473465620674,v
日,17,0.003922473465620674,m
国家,17,0.003922473465620674,n
研发,17,0.003922473465620674,j
采购,17,0.003922473465620674,v
未来,16,0.0036917397323488694,t
技术,16,0.0036917397323488694,n
导致,16,0.0036917397323488694,v
类,16,0.0036917397323488694,q
网络,15,0.003461005999077065,n
铁塔,15,0.003461005999077065,n
业绩,15,0.003461005999077065,n
不利,15,0.003461005999077065,a
相关,15,0.003461005999077065,v
变化,15,0.003461005999077065,vn
募集,15,0.003461005999077065,v
带来,14,0.003230272265805261,v
发生,14,0.003230272265805261,v
改革,14,0.003230272265805261,vn
抗生素,14,0.003230272265805261,nz
注册,14,0.003230272265805261,v
会,13,0.0029995385325334565,v
新,13,0.0029995385325334565,a
一致性,13,0.0029995385325334565,n
实施,13,0.0029995385325334565,v
税率,13,0.0029995385325334565,n
持续,12,0.0027688047992616522,vd
我国,12,0.0027688047992616522,r
质量,12,0.0027688047992616522,n
员工,12,0.0027688047992616522,n
增加,12,0.0027688047992616522,v
产生,12,0.0027688047992616522,n
原材料,12,0.0027688047992616522,n
较大,12,0.0027688047992616522,a
下降,12,0.0027688047992616522,v
固定资产,12,0.0027688047992616522,l
新药,12,0.0027688047992616522,n
枸地,12,0.0027688047992616522,n
氯雷,12,0.0027688047992616522,n
定,12,0.0027688047992616522,v
建设,11,0.0025380710659898475,vn
重大,11,0.0025380710659898475,a
均,11,0.0025380710659898475,d
收入,11,0.0025380710659898475,v
原料,11,0.0025380710659898475,n
本次,11,0.0025380710659898475,r
净资产,11,0.0025380710659898475,n
胶囊,11,0.0025380710659898475,n
因素,10,0.0023073373327180432,n
波动,10,0.0023073373327180432,vn
造成,10,0.0023073373327180432,v
国内,10,0.0023073373327180432,s
销售收入,10,0.0023073373327180432,n
中,10,0.0023073373327180432,f
不断,10,0.0023073373327180432,d
标准,10,0.0023073373327180432,n
要求,10,0.0023073373327180432,v
证书,10,0.0023073373327180432,n
报告,10,0.0023073373327180432,n
期内,10,0.0023073373327180432,f
营业,10,0.0023073373327180432,n
完成,10,0.0023073373327180432,v
高新技术,10,0.0023073373327180432,n
发行人,10,0.0023073373327180432,n
合肥,10,0.0023073373327180432,n
客户,9,0.002076603599446239,n
直接,9,0.002076603599446239,ad
投入,9,0.002076603599446239,v
设备,9,0.002076603599446239,vn
进行,9,0.002076603599446239,v
取得,9,0.002076603599446239,v
制定,9,0.002076603599446239,v
人员,9,0.002076603599446239,n
应收,9,0.002076603599446239,v
账款,9,0.002076603599446239,n
最高,9,0.002076603599446239,a
形成,8,0.0018458698661744347,v
能力,8,0.0018458698661744347,n
需求,8,0.0018458698661744347,v
稳定,8,0.0018458698661744347,a
上述,8,0.0018458698661744347,b
业务,8,0.0018458698661744347,n
增长,8,0.0018458698661744347,v
存在,8,0.0018458698661744347,v
物理,8,0.0018458698661744347,n
完善,8,0.0018458698661744347,v
制度,8,0.0018458698661744347,n
执行,8,0.0018458698661744347,v
出现,8,0.0018458698661744347,v
规定,8,0.0018458698661744347,n
深圳市,8,0.0018458698661744347,ns
有效期,8,0.0018458698661744347,n
意见,8,0.0018458698661744347,n
当期,8,0.0018458698661744347,t
快速,7,0.0016151361329026304,d
加大,7,0.0016151361329026304,v
继续,7,0.0016151361329026304,v
高,7,0.0016151361329026304,a
连接,7,0.0016151361329026304,v
竞争,7,0.0016151361329026304,vn
方式,7,0.0016151361329026304,n
加强,7,0.0016151361329026304,v
措施,7,0.0016151361329026304,n
产品质量,7,0.0016151361329026304,n
扩大,7,0.0016151361329026304,v
调整,7,0.0016151361329026304,vn
存货,7,0.0016151361329026304,n
比例,7,0.0016151361329026304,n
规模,7,0.0016151361329026304,n
收益率,7,0.0016151361329026304,n
预期,7,0.0016151361329026304,vn
销售,7,0.0016151361329026304,vn
享受,7,0.0016151361329026304,v
所得税,7,0.0016151361329026304,n
优惠,7,0.0016151361329026304,vn
实际,7,0.0016151361329026304,n
前,7,0.0016151361329026304,f
部门,7,0.0016151361329026304,n
政府,7,0.0016151361329026304,n
临床,7,0.0016151361329026304,vn
工作,7,0.0016151361329026304,vn
三大,6,0.0013844023996308261,j
报告期,6,0.0013844023996308261,n
三,6,0.0013844023996308261,m
关系,6,0.0013844023996308261,n
有限公司,6,0.0013844023996308261,n
不确定性,6,0.0013844023996308261,n
取消,6,0.0013844023996308261,v
开展,6,0.0013844023996308261,v
原则,6,0.0013844023996308261,n
市场竞争,6,0.0013844023996308261,l
招标,6,0.0013844023996308261,n
面临,6,0.0013844023996308261,v
技术人员,6,0.0013844023996308261,n
签署,6,0.0013844023996308261,v
进一步,6,0.0013844023996308261,d
核心技术,6,0.0013844023996308261,n
未,6,0.0013844023996308261,d
问题,6,0.0013844023996308261,n
过程,6,0.0013844023996308261,n
有效,6,0.0013844023996308261,a
净利润,6,0.0013844023996308261,n
未能,6,0.0013844023996308261,v
水平,6,0.0013844023996308261,n
需要,6,0.0013844023996308261,v
审批,6,0.0013844023996308261,v
发行,6,0.0013844023996308261,v
总,6,0.0013844023996308261,b
定价,6,0.0013844023996308261,n
医保,6,0.0013844023996308261,j
品种,6,0.0013844023996308261,n
提出,6,0.0013844023996308261,v
两票,6,0.0013844023996308261,m
制,6,0.0013844023996308261,n
仿制,6,0.0013844023996308261,v
药,6,0.0013844023996308261,n
批件,6,0.0013844023996308261,n
医工,6,0.0013844023996308261,n
经销商,6,0.0013844023996308261,n
近年来,5,0.0011536686663590216,t
推进,5,0.0011536686663590216,v
宽带,5,0.0011536686663590216,n
解决方案,5,0.0011536686663590216,n
竞争力,5,0.0011536686663590216,n
提升,5,0.0011536686663590216,v
及时,5,0.0011536686663590216,c
大幅,5,0.0011536686663590216,d
保持,5,0.0011536686663590216,v
产品价格,5,0.0011536686663590216,n
知识产权,5,0.0011536686663590216,n
项,5,0.0011536686663590216,n
严格,5,0.0011536686663590216,ad
无法,5,0.0011536686663590216,n
成本,5,0.0011536686663590216,n
程度,5,0.0011536686663590216,n
情况,5,0.0011536686663590216,n
股本,5,0.0011536686663590216,n
股东,5,0.0011536686663590216,n
新增,5,0.0011536686663590216,v
折旧,5,0.0011536686663590216,v
盈利,5,0.0011536686663590216,n
实现,5,0.0011536686663590216,v
联合,5,0.0011536686663590216,v
通知,5,0.0011536686663590216,v
支付,5,0.0011536686663590216,v
机制,5,0.0011536686663590216,n
发布,5,0.0011536686663590216,v
再,5,0.0011536686663590216,d
需,5,0.0011536686663590216,v
更,5,0.0011536686663590216,d
环保,5,0.0011536686663590216,j
中国联通,4,0.0009229349330872173,nt
中国电信,4,0.0009229349330872173,nt
期,4,0.0009229349330872173,n
处于,4,0.0009229349330872173,v
地位,4,0.0009229349330872173,n
资本,4,0.0009229349330872173,n
提供,4,0.0009229349330872173,v
建立,4,0.0009229349330872173,v
下滑,4,0.0009229349330872173,v
股份,4,0.0009229349330872173,n
组织,4,0.0009229349330872173,v
大幅度,4,0.0009229349330872173,d
方面,4,0.0009229349330872173,n
优势,4,0.0009229349330872173,n
系,4,0.0009229349330872173,v
较强,4,0.0009229349330872173,a
专业,4,0.0009229349330872173,n
目前,4,0.0009229349330872173,t
市场需求,4,0.0009229349330872173,n
充分,4,0.0009229349330872173,ad
重要,4,0.0009229349330872173,a
压力,4,0.0009229349330872173,n
营销,4,0.0009229349330872173,vn
经营规模,4,0.0009229349330872173,n
工艺,4,0.0009229349330872173,n
协议,4,0.0009229349330872173,n
良好,4,0.0009229349330872173,a
包括,4,0.0009229349330872173,v
变动,4,0.0009229349330872173,vn
上市,4,0.0009229349330872173,ns
利润,4,0.0009229349330872173,n
净额,4,0.0009229349330872173,n
集中,4,0.0009229349330872173,v
全市,4,0.0009229349330872173,n
最低工资,4,0.0009229349330872173,n
元月,4,0.0009229349330872173,t
提高,4,0.0009229349330872173,v
特点,4,0.0009229349330872173,n
渠道,4,0.0009229349330872173,n
比重,4,0.0009229349330872173,n
低,4,0.0009229349330872173,a
收益,4,0.0009229349330872173,n
号,4,0.0009229349330872173,m
委员会,4,0.0009229349330872173,n
三年,4,0.0009229349330872173,m
委,4,0.0009229349330872173,zg
实行,4,0.0009229349330872173,v
零售,4,0.0009229349330872173,vn
限价,4,0.0009229349330872173,v
受,4,0.0009229349330872173,v
中标,4,0.0009229349330872173,n
积极,4,0.0009229349330872173,ad
医药,4,0.0009229349330872173,n
分类,4,0.0009229349330872173,n
流通,4,0.0009229349330872173,vn
推行,4,0.0009229349330872173,v
化学药品,4,0.0009229349330872173,n
制剂,4,0.0009229349330872173,n
片,4,0.0009229349330872173,q
原料药,4,0.0009229349330872173,n
恩瑞特,4,0.0009229349330872173,nr
药业,4,0.0009229349330872173,n
许可证,4,0.0009229349330872173,nr
人数,4,0.0009229349330872173,n
公司业绩,3,0.0006922011998154131,n
中国移动,3,0.0006922011998154131,nt
综合,3,0.0006922011998154131,vn
满足,3,0.0006922011998154131,v
供应商,3,0.0006922011998154131,n
正式,3,0.0006922011998154131,ad
共享,3,0.0006922011998154131,v
模式,3,0.0006922011998154131,n
适应,3,0.0006922011998154131,v
工业,3,0.0006922011998154131,n
信息化,3,0.0006922011998154131,n
全国,3,0.0006922011998154131,n
储备,3,0.0006922011998154131,vn
明显,3,0.0006922011998154131,a
制造,3,0.0006922011998154131,v
关键,3,0.0006922011998154131,n
基础,3,0.0006922011998154131,n
体制,3,0.0006922011998154131,n
开发,3,0.0006922011998154131,v
时,3,0.0006922011998154131,n
开拓,3,0.0006922011998154131,v
流失,3,0.0006922011998154131,v
扩张,3,0.0006922011998154131,v
人才,3,0.0006922011998154131,n
吸引,3,0.0006922011998154131,v
稳定性,3,0.0006922011998154131,n
侵害,3,0.0006922011998154131,v
创新,3,0.0006922011998154131,v
获得,3,0.0006922011998154131,v
登记,3,0.0006922011998154131,v
保护,3,0.0006922011998154131,v
保密,3,0.0006922011998154131,n
评估,3,0.0006922011998154131,vn
环节,3,0.0006922011998154131,n
加剧,3,0.0006922011998154131,v
毛利,3,0.0006922011998154131,nr
金额,3,0.0006922011998154131,n
上涨,3,0.0006922011998154131,v
产业政策,3,0.0006922011998154131,n
总资产,3,0.0006922011998154131,n
经营风险,3,0.0006922011998154131,n
劳动力,3,0.0006922011998154131,n
达到,3,0.0006922011998154131,v
阶段,3,0.0006922011998154131,n
单一,3,0.0006922011998154131,b
成功,3,0.0006922011998154131,a
相应,3,0.0006922011998154131,v
效益,3,0.0006922011998154131,n
到位,3,0.0006922011998154131,v
达产,3,0.0006922011998154131,v
万股,3,0.0006922011998154131,m
持有,3,0.0006922011998154131,v
印发,3,0.0006922011998154131,nz
绝大部分,3,0.0006922011998154131,m
零售价格,3,0.0006922011998154131,n
方法,3,0.0006922011998154131,n
将来,3,0.0006922011998154131,t
特殊,3,0.0006922011998154131,a
药物,3,0.0006922011998154131,n
盐酸,3,0.0006922011998154131,n
头孢,3,0.0006922011998154131,n
规范,3,0.0006922011998154131,n
制药,3,0.0006922011998154131,n
医药卫生,3,0.0006922011998154131,n
监管,3,0.0006922011998154131,vn
国务院办公厅,3,0.0006922011998154131,nt
公立医院,3,0.0006922011998154131,nt
疗效,3,0.0006922011998154131,n
批准,3,0.0006922011998154131,v
应,3,0.0006922011998154131,v
年底,3,0.0006922011998154131,t
不予,3,0.0006922011998154131,v
时间,3,0.0006922011998154131,n
批准文号,3,0.0006922011998154131,n
申请,3,0.0006922011998154131,v
负面影响,3,0.0006922011998154131,n
迅速,3,0.0006922011998154131,ad
难度,3,0.0006922011998154131,d
接受,3,0.0006922011998154131,v
利尿剂,3,0.0006922011998154131,n
正在,3,0.0006922011998154131,t
认证,3,0.0006922011998154131,v
离职,3,0.0006922011998154131,v
第四节,2,0.00046146746654360867,m
基础设施,2,0.00046146746654360867,n
依赖,2,0.00046146746654360867,v
开支,2,0.00046146746654360867,v
长期,2,0.00046146746654360867,d
合作,2,0.00046146746654360867,vn
中国,2,0.00046146746654360867,ns
成立,2,0.00046146746654360867,v
基站,2,0.00046146746654360867,n
运营,2,0.00046146746654360867,vn
设施,2,0.00046146746654360867,n
二,2,0.00046146746654360867,m
投资规模,2,0.00046146746654360867,n
进度,2,0.00046146746654360867,d
部,2,0.00046146746654360867,n
发放,2,0.00046146746654360867,v
牌照,2,0.00046146746654360867,n
限制,2,0.00046146746654360867,v
城市,2,0.00046146746654360867,ns
试验,2,0.00046146746654360867,vn
快速增长,2,0.00046146746654360867,n
大量,2,0.00046146746654360867,n
G,2,0.00046146746654360867,eng
前期,2,0.00046146746654360867,f
速度,2,0.00046146746654360867,n
快,2,0.00046146746654360867,a
把握,2,0.00046146746654360867,v
市场化,2,0.00046146746654360867,n
开发新,2,0.00046146746654360867,nz
富有,2,0.00046146746654360867,v
坚持,2,0.00046146746654360867,v
出,2,0.00046146746654360867,v
最新,2,0.00046146746654360867,d
竞争能力,2,0.00046146746654360867,n
四,2,0.00046146746654360867,m
一个,2,0.00046146746654360867,m
服务,2,0.00046146746654360867,vn
考虑,2,0.00046146746654360867,v
日海,2,0.00046146746654360867,ns
通讯,2,0.00046146746654360867,nz
五,2,0.00046146746654360867,m
高级,2,0.00046146746654360867,b
管理人员,2,0.00046146746654360867,n
现有,2,0.00046146746654360867,b
薪酬,2,0.00046146746654360867,n
方案,2,0.00046146746654360867,n
培训,2,0.00046146746654360867,vn
维持,2,0.00046146746654360867,v
队伍,2,0.00046146746654360867,n
优秀,2,0.00046146746654360867,a
加盟,2,0.00046146746654360867,ns
领先,2,0.00046146746654360867,n
持久性,2,0.00046146746654360867,n
六,2,0.00046146746654360867,m
遭受,2,0.00046146746654360867,v
共,2,0.00046146746654360867,d
专利,2,0.00046146746654360867,n
管理制度,2,0.00046146746654360867,n
成果,2,0.00046146746654360867,n
七,2,0.00046146746654360867,m
效果,2,0.00046146746654360867,n
成品,2,0.00046146746654360867,n
多个,2,0.00046146746654360867,m
活动,2,0.00046146746654360867,vn
声誉,2,0.00046146746654360867,n
八,2,0.00046146746654360867,m
九,2,0.00046146746654360867,m
持续增长,2,0.00046146746654360867,n
支出,2,0.00046146746654360867,v
自然灾害,2,0.00046146746654360867,l
环境,2,0.00046146746654360867,n
排除,2,0.00046146746654360867,v
期间,2,0.00046146746654360867,f
十,2,0.00046146746654360867,m
余额,2,0.00046146746654360867,n
23.09,2,0.00046146746654360867,m
周转率,2,0.00046146746654360867,n
加快,2,0.00046146746654360867,v
十一,2,0.00046146746654360867,m
光无源,2,0.00046146746654360867,l
器件,2,0.00046146746654360867,n
晶,2,0.00046146746654360867,nr
圆,2,0.00046146746654360867,vg
降低,2,0.00046146746654360867,v
上升,2,0.00046146746654360867,v
十二,2,0.00046146746654360867,m
预计,2,0.00046146746654360867,vn
生产工艺,2,0.00046146746654360867,n
十三,2,0.00046146746654360867,m
期末,2,0.00046146746654360867,t
较高,2,0.00046146746654360867,a
日常,2,0.00046146746654360867,d
营运,2,0.00046146746654360867,n
周期长,2,0.00046146746654360867,n
融资,2,0.00046146746654360867,vn
十四,2,0.00046146746654360867,m
不足,2,0.00046146746654360867,a
决定,2,0.00046146746654360867,v
资产,2,0.00046146746654360867,n
用于,2,0.00046146746654360867,v
厂房,2,0.00046146746654360867,n
十五,2,0.00046146746654360867,m
建设项目,2,0.00046146746654360867,n
具有,2,0.00046146746654360867,v
经济效益,2,0.00046146746654360867,n
募,2,0.00046146746654360867,vg
投,2,0.00046146746654360867,n
供求,2,0.00046146746654360867,v
进步,2,0.00046146746654360867,d
十六,2,0.00046146746654360867,m
即期,2,0.00046146746654360867,d
回报,2,0.00046146746654360867,v
摊,2,0.00046146746654360867,n
薄,2,0.00046146746654360867,a
加权,2,0.00046146746654360867,v
平均,2,0.00046146746654360867,a
短期内,2,0.00046146746654360867,n
增长幅度,2,0.00046146746654360867,l
低于,2,0.00046146746654360867,v
幅度,2,0.00046146746654360867,n
十七,2,0.00046146746654360867,m
计划,2,0.00046146746654360867,n
合计,2,0.00046146746654360867,vn
折旧费,2,0.00046146746654360867,n
消化,2,0.00046146746654360867,vn
十八,2,0.00046146746654360867,m
优惠政策,2,0.00046146746654360867,n
施行,2,0.00046146746654360867,v
年内,2,0.00046146746654360867,t
法定,2,0.00046146746654360867,n
科技,2,0.00046146746654360867,n
财政,2,0.00046146746654360867,n
国家税务局,2,0.00046146746654360867,nt
地方税务局,2,0.00046146746654360867,nt
颁发,2,0.00046146746654360867,v
证书编号,2,0.00046146746654360867,n
母公司,2,0.00046146746654360867,n
十九,2,0.00046146746654360867,m
陈登志,2,0.00046146746654360867,nr
张锋峰,2,0.00046146746654360867,nr
曾宪琦,2,0.00046146746654360867,nr
一致,2,0.00046146746654360867,d
能够,2,0.00046146746654360867,v
行使,2,0.00046146746654360867,n
表决权,2,0.00046146746654360867,v
公司章程,2,0.00046146746654360867,n
行为,2,0.00046146746654360867,v
一系列,2,0.00046146746654360867,m
下列,2,0.00046146746654360867,v
排列,2,0.00046146746654360867,v
发出,2,0.00046146746654360867,v
发改,2,0.00046146746654360867,v
麻醉药品,2,0.00046146746654360867,n
第一类,2,0.00046146746654360867,m
精神药品,2,0.00046146746654360867,n
暂时,2,0.00046146746654360867,d
出厂价格,2,0.00046146746654360867,n
外,2,0.00046146746654360867,f
予以,2,0.00046146746654360867,v
不再,2,0.00046146746654360867,d
分类管理,2,0.00046146746654360867,n
不同,2,0.00046146746654360867,a
基金,2,0.00046146746654360867,n
由医保,2,0.00046146746654360867,nr
会同,2,0.00046146746654360867,n
拟定,2,0.00046146746654360867,v
程序,2,0.00046146746654360867,n
规则,2,0.00046146746654360867,n
探索,2,0.00046146746654360867,v
引导,2,0.00046146746654360867,v
价格合理,2,0.00046146746654360867,n
零售价,2,0.00046146746654360867,n
终端,2,0.00046146746654360867,n
各地,2,0.00046146746654360867,r
特别,2,0.00046146746654360867,d
不断深入,2,0.00046146746654360867,i
控费,2,0.00046146746654360867,v
作用,2,0.00046146746654360867,v
强化,2,0.00046146746654360867,v
生产流程,2,0.00046146746654360867,l
正,2,0.00046146746654360867,d
日益,2,0.00046146746654360867,n
抗菌,2,0.00046146746654360867,n
用药,2,0.00046146746654360867,n
医疗机构,2,0.00046146746654360867,n
3064.10,2,0.00046146746654360867,m
5590.21,2,0.00046146746654360867,m
5887.39,2,0.00046146746654360867,m
6366.26,2,0.00046146746654360867,m
25.39,2,0.00046146746654360867,m
25.30,2,0.00046146746654360867,m
29.79,2,0.00046146746654360867,m
37.56,2,0.00046146746654360867,m
总体,2,0.00046146746654360867,n
趋势,2,0.00046146746654360867,n
重点,2,0.00046146746654360867,n
注射用,2,0.00046146746654360867,n
类药物,2,0.00046146746654360867,n
进入,2,0.00046146746654360867,v
体制改革,2,0.00046146746654360867,l
医疗卫生,2,0.00046146746654360867,n
深化,2,0.00046146746654360867,j
近期,2,0.00046146746654360867,t
医改,2,0.00046146746654360867,j
指导,2,0.00046146746654360867,n
销往,2,0.00046146746654360867,vn
开,2,0.00046146746654360867,v
一次,2,0.00046146746654360867,m
发票,2,0.00046146746654360867,n
试点,2,0.00046146746654360867,n
鼓励,2,0.00046146746654360867,v
医院,2,0.00046146746654360867,n
结算,2,0.00046146746654360867,v
配送,2,0.00046146746654360867,v
费用,2,0.00046146746654360867,n
须,2,0.00046146746654360867,d
基本,2,0.00046146746654360867,n
固体,2,0.00046146746654360867,a
逾期,2,0.00046146746654360867,t
产,2,0.00046146746654360867,n
苯磺酸,2,0.00046146746654360867,nz
氨氯地平,2,0.00046146746654360867,nz
属于,2,0.00046146746654360867,v
研,2,0.00046146746654360867,vn
氯吡,2,0.00046146746654360867,nz
格雷,2,0.00046146746654360867,nr
产业化,2,0.00046146746654360867,n
分散,2,0.00046146746654360867,v
产品销售,2,0.00046146746654360867,j
规模较,2,0.00046146746654360867,v
拥有,2,0.00046146746654360867,v
转让,2,0.00046146746654360867,v
具备,2,0.00046146746654360867,v
条件,2,0.00046146746654360867,n
国药准字,2,0.00046146746654360867,nz
车间,2,0.00046146746654360867,n
GMP,2,0.00046146746654360867,eng
子公司,2,0.00046146746654360867,n
技术转让,2,0.00046146746654360867,l
停止,2,0.00046146746654360867,v
包装,2,0.00046146746654360867,v
经销,2,0.00046146746654360867,vn
环境保护,2,0.00046146746654360867,n
已于,2,0.00046146746654360867,d
法律法规,2,0.00046146746654360867,n
认定,2,0.00046146746654360867,v
特许,2,0.00046146746654360867,d
执照,2,0.00046146746654360867,v
1.7,2,0.00046146746654360867,m
采取,2,0.00046146746654360867,v
内控,2,0.00046146746654360867,b
投产,2,0.00046146746654360867,vn
战略,2,0.00046146746654360867,n
管理层,2,0.00046146746654360867,n
决策,2,0.00046146746654360867,n
提供商,1,0.00023073373327180433,n
95.97,1,0.00023073373327180433,m
96.10,1,0.00023073373327180433,m
98.18,1,0.00023073373327180433,m
99.68,1,0.00023073373327180433,m
产业链,1,0.00023073373327180433,n
基础性,1,0.00023073373327180433,n
抓住,1,0.00023073373327180433,v
光纤,1,0.00023073373327180433,n
无线网络,1,0.00023073373327180433,n
机遇,1,0.00023073373327180433,n
丰富,1,0.00023073373327180433,a
系列,1,0.00023073373327180433,q
较好,1,0.00023073373327180433,a
信赖,1,0.00023073373327180433,n
同类,1,0.00023073373327180433,n
紧密,1,0.00023073373327180433,a
有利于,1,0.00023073373327180433,v
专注,1,0.00023073373327180433,v
机房,1,0.00023073373327180433,n
室内,1,0.00023073373327180433,s
分布,1,0.00023073373327180433,v
系统,1,0.00023073373327180433,n
维护,1,0.00023073373327180433,v
专业化,1,0.00023073373327180433,n
开启,1,0.00023073373327180433,v
附属,1,0.00023073373327180433,b
共建,1,0.00023073373327180433,v
全新,1,0.00023073373327180433,d
应对,1,0.00023073373327180433,v
固网,1,0.00023073373327180433,n
有序,1,0.00023073373327180433,n
混合,1,0.00023073373327180433,vn
组网,1,0.00023073373327180433,v
部向,1,0.00023073373327180433,n
力度,1,0.00023073373327180433,n
驱动,1,0.00023073373327180433,vn
无线通信,1,0.00023073373327180433,l
专门,1,0.00023073373327180433,n
FTTX,1,0.00023073373327180433,eng
G4G,1,0.00023073373327180433,eng
市场营销,1,0.00023073373327180433,n
大规模,1,0.00023073373327180433,b
启动,1,0.00023073373327180433,vn
系统工程,1,0.00023073373327180433,n
具体,1,0.00023073373327180433,a
密集型,1,0.00023073373327180433,n
升级换代,1,0.00023073373327180433,l
实力,1,0.00023073373327180433,n
要素,1,0.00023073373327180433,n
深刻理解,1,0.00023073373327180433,l
化为,1,0.00023073373327180433,v
导向,1,0.00023073373327180433,n
目标,1,0.00023073373327180433,n
依托,1,0.00023073373327180433,v
一支,1,0.00023073373327180433,m
高素质,1,0.00023073373327180433,nr
团队,1,0.00023073373327180433,n
创造力,1,0.00023073373327180433,n
整体,1,0.00023073373327180433,n
技术水平,1,0.00023073373327180433,n
领先地位,1,0.00023073373327180433,n
贴近,1,0.00023073373327180433,v
积极参与,1,0.00023073373327180433,i
行业标准,1,0.00023073373327180433,n
符合,1,0.00023073373327180433,v
升级,1,0.00023073373327180433,vn
层出不穷,1,0.00023073373327180433,i
越来越,1,0.00023073373327180433,d
跟进,1,0.00023073373327180433,v
国内外,1,0.00023073373327180433,s
ICT,1,0.00023073373327180433,eng
商,1,0.00023073373327180433,n
后续,1,0.00023073373327180433,v
新海,1,0.00023073373327180433,ns
宜,1,0.00023073373327180433,vg
构成,1,0.00023073373327180433,v
归因于,1,0.00023073373327180433,v
共同努力,1,0.00023073373327180433,l
劳动合同,1,0.00023073373327180433,l
合理,1,0.00023073373327180433,vn
股权,1,0.00023073373327180433,n
激励,1,0.00023073373327180433,v
员工福利,1,0.00023073373327180433,n
人才队伍,1,0.00023073373327180433,n
赢得,1,0.00023073373327180433,v
关键因素,1,0.00023073373327180433,nr
自主,1,0.00023073373327180433,v
专利证书,1,0.00023073373327180433,n
发明专利,1,0.00023073373327180433,l
实用新型,1,0.00023073373327180433,n
外观设计,1,0.00023073373327180433,n
计算机软件,1,0.00023073373327180433,n
著作权,1,0.00023073373327180433,n
申请专利,1,0.00023073373327180433,nr
手段,1,0.00023073373327180433,n
事件,1,0.00023073373327180433,n
机密,1,0.00023073373327180433,n
规范性,1,0.00023073373327180433,n
文件,1,0.00023073373327180433,n
泄漏,1,0.00023073373327180433,v
重大损失,1,0.00023073373327180433,n
Anixter,1,0.00023073373327180433,eng
统计,1,0.00023073373327180433,v
世界,1,0.00023073373327180433,n
非常,1,0.00023073373327180433,d
注重,1,0.00023073373327180433,v
性能,1,0.00023073373327180433,n
考核,1,0.00023073373327180433,vn
指标,1,0.00023073373327180433,n
ISO9001,1,0.00023073373327180433,eng
ISO14001,1,0.00023073373327180433,eng
OHSAS18001,1,0.00023073373327180433,eng
管理体系,1,0.00023073373327180433,n
内部,1,0.00023073373327180433,f
选择,1,0.00023073373327180433,v
来料,1,0.00023073373327180433,n
制程,1,0.00023073373327180433,n
验证,1,0.00023073373327180433,v
交付,1,0.00023073373327180433,v
售后服务,1,0.00023073373327180433,l
全过程,1,0.00023073373327180433,n
监控,1,0.00023073373327180433,vn
从未,1,0.00023073373327180433,d
纠纷,1,0.00023073373327180433,n
高精度,1,0.00023073373327180433,n
产品数量,1,0.00023073373327180433,n
数据,1,0.00023073373327180433,n
来源于,1,0.00023073373327180433,v
A股,1,0.00023073373327180433,n
上市公司,1,0.00023073373327180433,nt
ODN,1,0.00023073373327180433,eng
无线,1,0.00023073373327180433,n
接入,1,0.00023073373327180433,v
传输网,1,0.00023073373327180433,n
招投标,1,0.00023073373327180433,j
随之,1,0.00023073373327180433,p
方向,1,0.00023073373327180433,n
43408.49,1,0.00023073373327180433,m
49052.37,1,0.00023073373327180433,m
76678.53,1,0.00023073373327180433,m
34329.54,1,0.00023073373327180433,m
扣除非,1,0.00023073373327180433,i
经常性,1,0.00023073373327180433,n
损益,1,0.00023073373327180433,n
5044.45,1,0.00023073373327180433,m
5576.47,1,0.00023073373327180433,m
6111.28,1,0.00023073373327180433,m
3455.08,1,0.00023073373327180433,m
保持稳定,1,0.00023073373327180433,n
对外,1,0.00023073373327180433,s
不可抗力,1,0.00023073373327180433,l
当年,1,0.00023073373327180433,t
上年,1,0.00023073373327180433,t
9297.57,1,0.00023073373327180433,m
18311.75,1,0.00023073373327180433,m
30460.28,1,0.00023073373327180433,m
28950.26,1,0.00023073373327180433,m
31.70,1,0.00023073373327180433,m
39.75,1,0.00023073373327180433,m
33.15,1,0.00023073373327180433,m
2.79,1,0.00023073373327180433,m
2.13,1,0.00023073373327180433,m
2.09,1,0.00023073373327180433,m
1.47,1,0.00023073373327180433,m
化,1,0.00023073373327180433,n
周转,1,0.00023073373327180433,nr
引致,1,0.00023073373327180433,v
资金占用,1,0.00023073373327180433,n
钣金,1,0.00023073373327180433,n
塑胶,1,0.00023073373327180433,n
电子,1,0.00023073373327180433,n
元器件,1,0.00023073373327180433,n
生产成本,1,0.00023073373327180433,l
88.96,1,0.00023073373327180433,m
90.15,1,0.00023073373327180433,m
91.12,1,0.00023073373327180433,m
90.14,1,0.00023073373327180433,m
厂商,1,0.00023073373327180433,n
大都,1,0.00023073373327180433,ns
韩国,1,0.00023073373327180433,ns
日本,1,0.00023073373327180433,ns
台湾,1,0.00023073373327180433,ns
优化,1,0.00023073373327180433,vn
工艺流程,1,0.00023073373327180433,n
使用,1,0.00023073373327180433,v
经济,1,0.00023073373327180433,n
国民收入,1,0.00023073373327180433,n
所在地,1,0.00023073373327180433,n
深圳,1,0.00023073373327180433,ns
地区,1,0.00023073373327180433,n
例,1,0.00023073373327180433,v
努力,1,0.00023073373327180433,ad
改进,1,0.00023073373327180433,v
自动化,1,0.00023073373327180433,l
消除,1,0.00023073373327180433,v
价格上涨,1,0.00023073373327180433,l
17191.67,1,0.00023073373327180433,m
21676.72,1,0.00023073373327180433,m
24992.43,1,0.00023073373327180433,m
37074.64,1,0.00023073373327180433,m
付款,1,0.00023073373327180433,v
实力雄厚,1,0.00023073373327180433,l
资信,1,0.00023073373327180433,n
账龄,1,0.00023073373327180433,n
一年,1,0.00023073373327180433,m
以内,1,0.00023073373327180433,f
占比,1,0.00023073373327180433,v
坏账,1,0.00023073373327180433,n
拓展,1,0.00023073373327180433,v
司,1,0.00023073373327180433,nr
显现,1,0.00023073373327180433,v
带来不利,1,0.00023073373327180433,v
4.20,1,0.00023073373327180433,m
2.80,1,0.00023073373327180433,m
1.79,1,0.00023073373327180433,m
1.42,1,0.00023073373327180433,m
比较,1,0.00023073373327180433,d
流动性,1,0.00023073373327180433,n
占用,1,0.00023073373327180433,v
优先,1,0.00023073373327180433,vn
购置,1,0.00023073373327180433,v
流动资产,1,0.00023073373327180433,l
所需,1,0.00023073373327180433,n
机器设备,1,0.00023073373327180433,n
项目风险,1,0.00023073373327180433,n
技术改造,1,0.00023073373327180433,l
中心,1,0.00023073373327180433,n
服务体系,1,0.00023073373327180433,n
补充,1,0.00023073373327180433,v
流动资金,1,0.00023073373327180433,n
项目选择,1,0.00023073373327180433,nr
市场调研,1,0.00023073373327180433,n
可行性,1,0.00023073373327180433,n
论证,1,0.00023073373327180433,n
市场前景,1,0.00023073373327180433,n
密切相关,1,0.00023073373327180433,l
26.19,1,0.00023073373327180433,m
20.30,1,0.00023073373327180433,m
9.51,1,0.00023073373327180433,m
建设周期,1,0.00023073373327180433,n
尚需,1,0.00023073373327180433,n
一段时间,1,0.00023073373327180433,l
每股,1,0.00023073373327180433,r
财务指标,1,0.00023073373327180433,n
18285.05,1,0.00023073373327180433,m
每年,1,0.00023073373327180433,r
1544.06,1,0.00023073373327180433,m
足以,1,0.00023073373327180433,v
抵消,1,0.00023073373327180433,v
税收政策,1,0.00023073373327180433,n
国发,1,0.00023073373327180433,nt
文,1,0.00023073373327180433,n
原,1,0.00023073373327180433,n
新税法,1,0.00023073373327180433,n
过渡,1,0.00023073373327180433,v
始,1,0.00023073373327180433,vg
GR201244200417,1,0.00023073373327180433,eng
GF201544200270,1,0.00023073373327180433,eng
5796.89,1,0.00023073373327180433,m
48.31,1,0.00023073373327180433,m
仍为,1,0.00023073373327180433,d
行动,1,0.00023073373327180433,vn
三位,1,0.00023073373327180433,m
股东大会,1,0.00023073373327180433,n
董事会,1,0.00023073373327180433,n
真实,1,0.00023073373327180433,d
意愿,1,0.00023073373327180433,n
选举,1,0.00023073373327180433,v
间接,1,0.00023073373327180433,b
挑选,1,0.00023073373327180433,v
确定,1,0.00023073373327180433,v
股利,1,0.00023073373327180433,n
分配,1,0.00023073373327180433,vn
促成,1,0.00023073373327180433,v
兼并,1,0.00023073373327180433,v
收购,1,0.00023073373327180433,v
修改,1,0.00023073373327180433,v
中小,1,0.00023073373327180433,j
股票,1,0.00023073373327180433,n
涉及,1,0.00023073373327180433,v
购买,1,0.00023073373327180433,v
公司股票,1,0.00023073373327180433,n
敬请,1,0.00023073373327180433,v
投资者,1,0.00023073373327180433,n
资料,1,0.00023073373327180433,n
一并,1,0.00023073373327180433,d
重要性,1,0.00023073373327180433,n
投资决策,1,0.00023073373327180433,n
大小,1,0.00023073373327180433,b
表明,1,0.00023073373327180433,v
次序,1,0.00023073373327180433,n
原有,1,0.00023073373327180433,v
发改委,1,0.00023073373327180433,j
仅,1,0.00023073373327180433,d
天花板,1,0.00023073373327180433,n
标价,1,0.00023073373327180433,n
销售价格,1,0.00023073373327180433,n
省级,1,0.00023073373327180433,b
统一,1,0.00023073373327180433,vn
已经,1,0.00023073373327180433,d
约束,1,0.00023073373327180433,vn
实际上,1,0.00023073373327180433,d
远,1,0.00023073373327180433,a
出厂价,1,0.00023073373327180433,n
有限,1,0.00023073373327180433,a
一种,1,0.00023073373327180433,m
商品,1,0.00023073373327180433,n
人民,1,0.00023073373327180433,n
生命,1,0.00023073373327180433,vn
健康,1,0.00023073373327180433,a
尤其,1,0.00023073373327180433,d
长,1,0.00023073373327180433,a
复杂,1,0.00023073373327180433,a
特殊性,1,0.00023073373327180433,n
存储,1,0.00023073373327180433,j
运输,1,0.00023073373327180433,vn
差错,1,0.00023073373327180433,n
化学,1,0.00023073373327180433,n
医疗事故,1,0.00023073373327180433,n
滥用,1,0.00023073373327180433,v
与此相关,1,0.00023073373327180433,l
耐药,1,0.00023073373327180433,nz
细菌,1,0.00023073373327180433,n
增多,1,0.00023073373327180433,v
现象,1,0.00023073373327180433,n
社会舆论,1,0.00023073373327180433,l
关注,1,0.00023073373327180433,v
分级管理,1,0.00023073373327180433,l
限抗,1,0.00023073373327180433,v
格局,1,0.00023073373327180433,n
产业,1,0.00023073373327180433,n
更加,1,0.00023073373327180433,d
使用量,1,0.00023073373327180433,n
呈现,1,0.00023073373327180433,v
替安,1,0.00023073373327180433,v
替加,1,0.00023073373327180433,v
环素,1,0.00023073373327180433,n
省市,1,0.00023073373327180433,n
挂网,1,0.00023073373327180433,v
销量,1,0.00023073373327180433,n
显著,1,0.00023073373327180433,a
略有,1,0.00023073373327180433,v
回升,1,0.00023073373327180433,v
应用,1,0.00023073373327180433,v
数量,1,0.00023073373327180433,n
近年,1,0.00023073373327180433,t
利尿,1,0.00023073373327180433,n
更多,1,0.00023073373327180433,d
现有企业,1,0.00023073373327180433,n
领域,1,0.00023073373327180433,n
市场份额,1,0.00023073373327180433,n
构成威胁,1,0.00023073373327180433,n
国际,1,0.00023073373327180433,n
大型,1,0.00023073373327180433,b
挤占,1,0.00023073373327180433,v
事业,1,0.00023073373327180433,n
管理体制,1,0.00023073373327180433,n
运行机制,1,0.00023073373327180433,n
保障,1,0.00023073373327180433,v
带量,1,0.00023073373327180433,v
二次,1,0.00023073373327180433,m
议价,1,0.00023073373327180433,n
卫,1,0.00023073373327180433,n
计委,1,0.00023073373327180433,n
落实,1,0.00023073373327180433,a
全面,1,0.00023073373327180433,n
构建,1,0.00023073373327180433,v
新机制,1,0.00023073373327180433,n
细化,1,0.00023073373327180433,n
出台,1,0.00023073373327180433,v
陆续,1,0.00023073373327180433,d
各省市,1,0.00023073373327180433,ns
价格下降,1,0.00023073373327180433,n
此项,1,0.00023073373327180433,r
旨在,1,0.00023073373327180433,v
购销,1,0.00023073373327180433,v
秩序,1,0.00023073373327180433,n
缩减,1,0.00023073373327180433,v
药价,1,0.00023073373327180433,n
目的,1,0.00023073373327180433,n
任务,1,0.00023073373327180433,n
国办发,1,0.00023073373327180433,j
省份,1,0.00023073373327180433,n
全省,1,0.00023073373327180433,n
范围,1,0.00023073373327180433,n
货款,1,0.00023073373327180433,n
策略,1,0.00023073373327180433,n
国务院,1,0.00023073373327180433,nt
医疗器械,1,0.00023073373327180433,n
审评,1,0.00023073373327180433,v
凡未,1,0.00023073373327180433,d
原研,1,0.00023073373327180433,n
目录,1,0.00023073373327180433,n
版,1,0.00023073373327180433,n
日前,1,0.00023073373327180433,t
口服,1,0.00023073373327180433,n
有效性,1,0.00023073373327180433,n
情形,1,0.00023073373327180433,n
首家,1,0.00023073373327180433,m
相同,1,0.00023073373327180433,d
原则上,1,0.00023073373327180433,d
前要,1,0.00023073373327180433,b
推广,1,0.00023073373327180433,v
高科技,1,0.00023073373327180433,nz
高附加值,1,0.00023073373327180433,n
人员素质,1,0.00023073373327180433,n
办法,1,0.00023073373327180433,n
法规,1,0.00023073373327180433,n
研究,1,0.00023073373327180433,vn
最终,1,0.00023073373327180433,d
失败,1,0.00023073373327180433,v
回收,1,0.00023073373327180433,v
研制开发,1,0.00023073373327180433,nz
规模化,1,0.00023073373327180433,n
工业化生产,1,0.00023073373327180433,n
技术指标,1,0.00023073373327180433,n
相对,1,0.00023073373327180433,d
小试,1,0.00023073373327180433,n
中试,1,0.00023073373327180433,j
往往,1,0.00023073373327180433,t
发生变化,1,0.00023073373327180433,l
试生产,1,0.00023073373327180433,n
身体健康,1,0.00023073373327180433,l
生命安全,1,0.00023073373327180433,nz
推向市场,1,0.00023073373327180433,n
认同,1,0.00023073373327180433,v
安,1,0.00023073373327180433,ns
孟多,1,0.00023073373327180433,nr
匹,1,0.00023073373327180433,m
莫德,1,0.00023073373327180433,nr
中间体,1,0.00023073373327180433,n
碳酸氢钠,1,0.00023073373327180433,nz
氢氧化钠,1,0.00023073373327180433,nz
乙醇,1,0.00023073373327180433,n
微晶,1,0.00023073373327180433,n
纤维素,1,0.00023073373327180433,n
辅料,1,0.00023073373327180433,n
多种类型,1,0.00023073373327180433,n
包装物,1,0.00023073373327180433,l
年前,1,0.00023073373327180433,t
五大,1,0.00023073373327180433,j
总金额,1,0.00023073373327180433,n
2135.84,1,0.00023073373327180433,m
3567.23,1,0.00023073373327180433,m
3666.89,1,0.00023073373327180433,m
3327.86,1,0.00023073373327180433,m
采购额,1,0.00023073373327180433,n
60.15,1,0.00023073373327180433,m
57.94,1,0.00023073373327180433,m
50.14,1,0.00023073373327180433,m
53.79,1,0.00023073373327180433,m
供应,1,0.00023073373327180433,vn
充足,1,0.00023073373327180433,a
单价,1,0.00023073373327180433,n
呈,1,0.00023073373327180433,v
供求关系,1,0.00023073373327180433,l
免疫调节,1,0.00023073373327180433,n
抗病毒,1,0.00023073373327180433,n
心脑血管,1,0.00023073373327180433,n
产品种类,1,0.00023073373327180433,n
结构,1,0.00023073373327180433,n
较为,1,0.00023073373327180433,d
产品类别,1,0.00023073373327180433,n
3548.25,1,0.00023073373327180433,m
6484.73,1,0.00023073373327180433,m
5735.91,1,0.00023073373327180433,m
4160.26,1,0.00023073373327180433,m
29.41,1,0.00023073373327180433,m
29.34,1,0.00023073373327180433,m
29.02,1,0.00023073373327180433,m
24.54,1,0.00023073373327180433,m
缺乏,1,0.00023073373327180433,v
财务状况,1,0.00023073373327180433,n
申报,1,0.00023073373327180433,nz
双方,1,0.00023073373327180433,n
并于,1,0.00023073373327180433,c
H20090105,1,0.00023073373327180433,eng
H20090104,1,0.00023073373327180433,eng
改造,1,0.00023073373327180433,v
异地,1,0.00023073373327180433,n
重建,1,0.00023073373327180433,a
增量,1,0.00023073373327180433,n
承接,1,0.00023073373327180433,v
硬件,1,0.00023073373327180433,n
合同书,1,0.00023073373327180433,n
拟将,1,0.00023073373327180433,d
817.07,1,0.00023073373327180433,m
1983.57,1,0.00023073373327180433,m
2050.11,1,0.00023073373327180433,m
1728.51,1,0.00023073373327180433,m
6.77,1,0.00023073373327180433,m
8.98,1,0.00023073373327180433,m
10.37,1,0.00023073373327180433,m
10.20,1,0.00023073373327180433,m
451.23,1,0.00023073373327180433,m
1106.92,1,0.00023073373327180433,m
1270.61,1,0.00023073373327180433,m
902.31,1,0.00023073373327180433,m
总额,1,0.00023073373327180433,n
5.74,1,0.00023073373327180433,m
8.15,1,0.00023073373327180433,m
10.74,1,0.00023073373327180433,m
9.45,1,0.00023073373327180433,m
何广卫,1,0.00023073373327180433,nr
产品开发,1,0.00023073373327180433,l
终止,1,0.00023073373327180433,v
约定,1,0.00023073373327180433,v
完毕,1,0.00023073373327180433,v
库存,1,0.00023073373327180433,n
尽快,1,0.00023073373327180433,d
采用,1,0.00023073373327180433,v
代理,1,0.00023073373327180433,n
区域,1,0.00023073373327180433,n
覆盖,1,0.00023073373327180433,v
产品代理,1,0.00023073373327180433,n
11103.98,1,0.00023073373327180433,m
20132.78,1,0.00023073373327180433,m
17892.84,1,0.00023073373327180433,m
15131.44,1,0.00023073373327180433,m
主营业务,1,0.00023073373327180433,n
92.11,1,0.00023073373327180433,m
92.07,1,0.00023073373327180433,m
91.85,1,0.00023073373327180433,m
89.27,1,0.00023073373327180433,m
覆盖范围,1,0.00023073373327180433,n
风险管理,1,0.00023073373327180433,n
管理混乱,1,0.00023073373327180433,l
违法,1,0.00023073373327180433,vn
违规,1,0.00023073373327180433,vn
法律纠纷,1,0.00023073373327180433,z
区域性,1,0.00023073373327180433,n
重视,1,0.00023073373327180433,v
水污染,1,0.00023073373327180433,b
排放,1,0.00023073373327180433,v
全面实施,1,0.00023073373327180433,n
修订,1,0.00023073373327180433,v
法,1,0.00023073373327180433,j
地方,1,0.00023073373327180433,n
颁布,1,0.00023073373327180433,v
进一步提高,1,0.00023073373327180433,i
再次,1,0.00023073373327180433,d
所得税法,1,0.00023073373327180433,n
期限,1,0.00023073373327180433,n
之后,1,0.00023073373327180433,f
重续,1,0.00023073373327180433,a
机构,1,0.00023073373327180433,n
期满,1,0.00023073373327180433,v
重新,1,0.00023073373327180433,a
延续,1,0.00023073373327180433,v
届满时,1,0.00023073373327180433,n
换领,1,0.00023073373327180433,v
新证,1,0.00023073373327180433,n
更新,1,0.00023073373327180433,d
正常,1,0.00023073373327180433,d
失密,1,0.00023073373327180433,a
1.9,1,0.00023073373327180433,m
不会,1,0.00023073373327180433,v
参与,1,0.00023073373327180433,v
增资,1,0.00023073373327180433,v
扩股,1,0.00023073373327180433,v
逐年,1,0.00023073373327180433,d
待遇,1,0.00023073373327180433,n
效,1,0.00023073373327180433,ng
组成部分,1,0.00023073373327180433,l
赖以生存,1,0.00023073373327180433,l
防止,1,0.00023073373327180433,v
外泄,1,0.00023073373327180433,v
职责,1,0.00023073373327180433,n
保密制度,1,0.00023073373327180433,n
防范措施,1,0.00023073373327180433,n
得不到,1,0.00023073373327180433,v
泄密,1,0.00023073373327180433,v
所拟,1,0.00023073373327180433,b
建成,1,0.00023073373327180433,v
到达,1,0.00023073373327180433,v
段,1,0.00023073373327180433,q
按时,1,0.00023073373327180433,d
建成投产,1,0.00023073373327180433,j
大幅度提高,1,0.00023073373327180433,l
新建,1,0.00023073373327180433,ns
试产,1,0.00023073373327180433,vn
磨合,1,0.00023073373327180433,v
如期,1,0.00023073373327180433,t
顺利,1,0.00023073373327180433,ad
8.70,1,0.00023073373327180433,m
18.53,1,0.00023073373327180433,m
18.69,1,0.00023073373327180433,m
22.30,1,0.00023073373327180433,m
经历,1,0.00023073373327180433,n
竣工,1,0.00023073373327180433,v
验收,1,0.00023073373327180433,v
在短期内,1,0.00023073373327180433,l
同步,1,0.00023073373327180433,d
以前年度,1,0.00023073373327180433,l
有所,1,0.00023073373327180433,n
不断扩大,1,0.00023073373327180433,n
资源整合,1,0.00023073373327180433,n
科研开发,1,0.00023073373327180433,nt
资本运作,1,0.00023073373327180433,n
运作,1,0.00023073373327180433,vn
业务素质,1,0.00023073373327180433,n
管理水平,1,0.00023073373327180433,n
曹于平,1,0.00023073373327180433,nr
姜晓群,1,0.00023073373327180433,nr
4094.19,1,0.00023073373327180433,m
68.23,1,0.00023073373327180433,m
二人,1,0.00023073373327180433,nrt
绝对,1,0.00023073373327180433,d
控股,1,0.00023073373327180433,v
议事规则,1,0.00023073373327180433,n
治理,1,0.00023073373327180433,v
做,1,0.00023073373327180433,v
限制性,1,0.00023073373327180433,n
安排,1,0.00023073373327180433,v
利用,1,0.00023073373327180433,n
人事安排,1,0.00023073373327180433,nt
关联,1,0.00023073373327180433,ns
交易,1,0.00023073373327180433,n
利润分配,1,0.00023073373327180433,n
事宜,1,0.00023073373327180433,n
科学性,1,0.00023073373327180433,n
合理性,1,0.00023073373327180433,n
损害,1,0.00023073373327180433,v
利益,1,0.00023073373327180433,n
